XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment and Related Information
12 Months Ended
Dec. 31, 2011
Segment and Related Information  
Segment and Related Information

(10) Segment and Related Information

 

The Company operates in one segment, which performs research and development activities related to Ampligen® and other drugs under development, and sales and marketing of Alferon®. The Company's revenues for the three year period ended December 31, 2011, were earned in the United States.

 

The Company employs an insignificant amount of net property and equipment in its foreign operations, which has minimal activity.